CYTOVATION ASA
Operating
a) Forskning, utvikling og industrialisering innen genterapi og
kreftbehanling. b) Kommersialisere resultater av forskning og
utvikling på dette området. Drive konsulentvirksomhet eller forestå
underleveranser relatert til formål som beskrevet i pkt. a og b.
Selskapets formål kan også oppnås ved å erverve eiendeler i andre
selskaper og delta i annen virksomhet.
Forskning, utvikling og industrialisering innen genterapi og
kreftbehandling. Kommersialisering av resultater av forskning og
utvikling på dette området.
Organization
- CEO
- LP
- Chairman of the board
- SC
- Years since formation
- 25 years
- since Sep 6, 2001
- Type
- Public limited company
- VAT registered
- No
- Number of employees
- 0
Ownership
- Number of shares and share classes
- 242,417
- 1 share class
- Total number of shareholders
- 20
- 14 companies, 6 persons
Financials
- Annual total result 2024
- -62,895,103
- NOK
- Total equity 2024
- -93,331,724
- NOK
Last update: Dec 12, 2025
Locations
- Company addressSolheimsgaten 11 5058 BERGEN, NorgeCopied!
Management
Management / administration
| Name | Role | Shares |
|---|---|---|
LP | Managing Director/CEO | 9.92 % indirectly |
Board
| Name | Role | Shares |
|---|---|---|
SC | Chairman | 1.84 % indirectly |
OH 1965 | Board Member | - |
EA | Board Member | - |
MW | Board Member | - |
KS | Board Member | - |
Others
| Name | Role | Shares |
|---|---|---|
| Auditor | - | |
| Accountant | - |
Top 10 individual shareholders
| Name | Role | Shares |
|---|---|---|
LP | Managing Director/CEO | 9.92 % indirectly |
PE | - | 9.9 % directly |
RB 1953 | - | 9.86 % directly |
TS 1972 | - | 2.88 % indirectly |
ME | - | 2.48 % indirectly |
KI | - | 2.2 % directly |
PH 1977 | - | 2.19 % indirectly |
TM | - | 2 % indirectly |
PN 1963 | - | 1.89 % indirectly |
SC | Chairman | 1.84 % indirectly |
Last update: May 13, 2025
Ownership
Company shareholders
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
| NO0012518952 | 83,746 | 34.55 % | |
| NO0012518952 | 47,700 | 19.68 % | |
| NO0012518952 | 24,052 | 9.92 % | |
PE | NO0012518952 | 23,994 | 9.9 % |
RB 1953 | NO0012518952 | 23,900 | 9.86 % |
| NO0012518952 | 10,680 | 4.41 % | |
| NO0012518952 | 6,995 | 2.89 % | |
| NO0012518952 | 5,612 | 2.32 % | |
KI | NO0012518952 | 5,339 | 2.2 % |
| NO0012518952 | 4,272 | 1.76 % | |
JA | NO0012518952 | 1,500 | 0.62 % |
| NO0012518952 | 1,323 | 0.55 % | |
| NO0012518952 | 944 | 0.39 % | |
| NO0012518952 | 814 | 0.34 % | |
ØG 1945 | NO0012518952 | 500 | 0.21 % |
| NO0012518952 | 464 | 0.19 % | |
| NO0012518952 | 281 | 0.12 % | |
| NO0012518952 | 171 | 0.07 % | |
ØS 1966 | NO0012518952 | 107 | 0.04 % |
| NO0012518952 | 22 | < 0.01 % |
Shares owned by the CYTOVATION ASA
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
| NO0012518952 | 6,995 | 2.89 % |
Last update: Jun 2, 2025
Financials
in NOK
Summary
| Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total operating income | 0 | 0 | 0 | 0 |
Annual Total Result | -62,895,103 | -81,511,885 | -122,909,417 | -34,365,250 |
Total assets | 15,779,127 | 78,156,381 | 83,917,564 | 107,451,738 |
Total liabilities | 109,110,850 | 108,593,001 | 32,842,299 | 20,341,570 |
Total equity | -93,331,724 | -30,436,620 | 51,075,265 | 87,110,169 |
P&L
| Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total operating income | 0 | 0 | 0 | 0 |
Total operating costs | 54,807,862 | 77,245,362 | 122,064,133 | 33,705,659 |
Operating result | -54,807,862 | -77,245,362 | -122,064,133 | -33,705,659 |
Financial income/costs | -8,087,242 | -4,266,523 | -845,284 | -659,591 |
Profit before tax | -62,895,103 | -81,511,885 | -122,909,417 | -34,365,250 |
Total tax & extraordinary income/cost | 0 | 0 | 0 | 0 |
Annual Total Result | -62,895,103 | -81,511,885 | -122,909,417 | -34,365,250 |
Balance overview
| Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total fixed assets | 242,595 | 274,258 | 94,163 | 31,663 |
Total current assets | 15,536,531 | 77,882,122 | 83,823,401 | 107,420,075 |
Total assets | 15,779,127 | 78,156,381 | 83,917,564 | 107,451,738 |
Short term debt | 8,872,317 | 17,467,062 | 21,936,315 | 9,435,586 |
Long term debt | 100,238,533 | 91,125,939 | 10,905,984 | 10,905,984 |
Total liabilities | 109,110,850 | 108,593,001 | 32,842,299 | 20,341,570 |
Contributed capital | 1,212,085 | 1,212,085 | 51,075,265 | 99,107,132 |
Retained earnings | -94,543,809 | -31,648,705 | 0 | -11,996,963 |
Total equity | -93,331,724 | -30,436,620 | 51,075,265 | 87,110,169 |
Total equity and liabilities | 15,779,127 | 78,156,381 | 83,917,564 | 107,451,738 |
Classification
21st company classification
BETA
Small company
Type of organization
Public limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises